Beam Therapeutics Inc. (NASDAQ:BEAM) Financings

Beam Therapeutics Inc.

Financings

RaiseDate
Public offering of common stock and pre-funded warrants
Announced: about US$500M · US$28.48 a share · J.P. Morgan +4
Dealers: J.P. Morgan (co-lead), Jefferies (co-lead), Cantor (co-lead), Citigroup (co-lead), Wells Fargo Securities (co-lead)
Use of proceeds: Advancing its base editing platform and programs, BEAM-101 BLA and pre-commercial work, BEAM-302 and ESCAPE trials, and general corporate purposes
Mar 10, 2025

Read by 6ix AI from the company's releases